Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

2.23
-0.1100-4.70%
Post-market: 2.230.00000.00%19:41 EDT
Volume:14.75M
Turnover:34.35M
Market Cap:744.67M
PE:-1.81
High:2.48
Open:2.39
Low:2.22
Close:2.34
Loading ...

Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Yesterday

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Iovance Biotherapeutics appoints Roche as CFO

TIPRANKS
·
15 Jul

Goldman Sachs Downgrades Iovance Biotherapeutics to Sell From Buy, Adjusts Price Target to $1 From $8

MT Newswires Live
·
15 Jul

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

THOMSON REUTERS
·
15 Jul

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

GlobeNewswire
·
15 Jul

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

TIPRANKS
·
15 Jul

Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study

MT Newswires Live
·
14 Jul

Iovance Biotherapeutics Unveils Corporate Presentation Highlighting Global Leadership and Pipeline in TIL Therapy for Cancer

Reuters
·
14 Jul

Iovance Biotherapeutics announces real-world study data on Amtagvi

TIPRANKS
·
14 Jul

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients With Advanced Melanoma

THOMSON REUTERS
·
14 Jul

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

GlobeNewswire
·
14 Jul

Iovance Biotherapeutics Files Initial Ownership Statement for Matthew W. Rosinack, SVP Finance

Reuters
·
11 Jul

Press Release: Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy

Dow Jones
·
11 Jul

Is This Beaten-Down Stock a Millionaire Maker?

Motley Fool
·
06 Jul

Iovance Biotherapeutics Inc - Matthew Rosinack Appointed Interim Principal Financial Officer - SEC Filing

THOMSON REUTERS
·
04 Jul

Iovance Biotherapeutics Appoints Matthew W. Rosinack as Interim Principal Financial Officer Following Departure of Jean-Marc Bellemin

Reuters
·
04 Jul

Iovance Biotherapeutics Q2 Revenue USD 49.3 Million

THOMSON REUTERS
·
01 Jul

BRIEF-Iovance Biotherapeutics Says Confirming Resignation Of Chief Financial Officer Jean-Marc Bellemin, Effective July 10, 2025

Reuters
·
26 Jun

Iovance Biotherapeutics Inc - Confirming Resignation of Chief Financial Officer Jean-Marc Bellemin, Effective July 10, 2025

THOMSON REUTERS
·
26 Jun